Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
N/A N=249 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
Phase 3 N=527 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Aspergillosis · Invasive Fungal Infection
Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 2 N=46 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Phase 3 N=459 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 4 N=71 An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
Pulmonary Fungal Infection
Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants
N/A N=116 An Observational Study of Fungal Biomarkers (MK-0000-089)
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Phase 3 N=585 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
Fungal Infections · Invasive Pulmonary Aspergillosis
Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 2 N=102 An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
Pulmonary Aspergillosis
Primary: Proportion of Participants Who Completed 12 Weeks of Therapy — 47; 23 Participants
Phase 4 N=35 Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over…
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Phase 3 N=62 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
Fungal Infection
Primary: Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment — 6; 32; 11; 10 Participants
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Phase 2 N=31 Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Invasive Aspergillosis
Primary: Percentage of Participants Who Experience One or More Treatment-related Adverse Events (AEs) — 14.3; 29.4 Percentage of participants
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 3 N=147 Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients
Possible Fungal Infection
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis — 6; 9 participants — p=0.258
N/A N=64 β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Invasive Candidiasis
Primary: Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients. — 3; 3; 19; 9 participants
Phase 4 N=70 Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Invasive Fungal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 55; 9 Participants
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
Phase 4 N=85 Negative Beta Glucan in ICU Patients
Candidemia
Primary: Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin — 0; 21 Participants
Phase 3 N=355 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
Invasive Fungal Disease
Primary: Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) — 7.9; 11.7 percentage of…
Phase 3 N=450 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Candidiasis, Invasive · Candidemia · Mycoses
Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…